COVID-19 Infections with and without Co-morbidities and Clinical Outcome

Beenish Ghafar a, Urooj Bhatti*, Shehmeen Khan b, Afsheen Abro b, Rubina Ahmedani a and Quratulain Memon c

a Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan.

b Bilawal Medical College, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan.

c Department of Surgical Ward, Jinnah Postgraduate Medical Center, Karachi, Pakistan.

Authors’ contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

ABSTRACT

Aim: To evaluate the clinical outcomes and severity of disease in COVID-19 patients presenting with and without comorbidities.

Study Design: Cross-sectional study.

Place and Duration: ICUs, wards of Jinnah Postgraduate Medical Center Karachi from March, to June 2021.

Methodology: The enrolled patients diagnosed with COVID-19 ie according to the provisional directions given by WHO, were assessed for clinical outcomes. Comorbidities were determined based on patients self-report on admission.

Results: Total 200 COVID patients were enrolled in the study, out of them 179 were with comorbidities like type 2 Diabetes mellitus, hypertension, cardiac disorders and asthma, while 21 COVID patients were with no co morbidity. In present study (n=200), 55.5% were belonging to the age group more than fifty five years old, there were 50.5% males and 29.5% patients came in the month of June 2021. There were 84% hypertensive, 54% were diabetic, 10% were Ischemic Heart Disease and 5% were Asthmatic patients. Clinical outcomes, i.e., pneumothorax, pulmonary embolism, Myocardial Infarction, septic shock, heart failure, Disseminated Intravascular Coagulation was compared
regarding associated co-morbidities at the time of admission, p-value was <0.01 and $\chi^2=20.15$.

Conclusion: COVID patients with comorbidities are more at risk of developing worst clinical outcomes.

Keywords: COVID 19; co-morbidities; clinical outcomes.

1. INTRODUCTION

Coronavirus disease 2019 (COVID-19) is a diverse infectious health condition concerning miscellaneous causal pathophysiological processes include endothelial damage, hyper inflammation, thrombotic microangiopathies as well as end-organ injuries [1]. It has been revealed as being caused by severe acute respiratory syndrome coronavirus 2 abbreviated as SARS-CoV-2 and it be initially recognized in December of 2019 in Wuhan city of China, and it had been spread world-wide and created HAVOC globally and culminated in increased mortality in about two hundred and twenty countries. Owing to constantly mounting numbers of confirmed cases as well as to stay away from devastating health systems, world health organization and community health system globally encompass prevention from spread of this outbreak via focus on social distancing, lockdowns and self-isolation [2]. Most of such patients suffer from pneumonia and present with augmented temperature as the first symptom, and the majority of them show characteristic manifestations of viral pneumonia on chest x-ray. Older age individuals and young adults with co-morbidities are vulnerable to respiratory failure and worse clinical outcomes [3]. Co-morbidities found significantly highly prevailing in severe COVID-19 cases, i.e., raised blood pressure but yet no understandable alliance exist between COVID-19 mortality and comorbidity [4].

COVID-19 patients mostly present with increased temperature, shortness of breath, cough, headache, muscle ache, sore throat, confusion, chest pain, nausea, vomiting and loose motions. In radiological findings, bilateral pneumonia found commonly, and to certain extent, mottling and ground-glass opacities and pneumothorax also found. Most of the patients also undergo respiratory distress syndrome and 11% worsened in a small period of time and pass away due to multiple organ failure [5]. Novel COVID-19 is well thought-out similar to SARS-CoV and it is suggested as invading human cells by means of angiotensin converting enzyme 2 (ACE2) receptors. Lung cells that contain ACE2 receptors, might be the actual target cells for COVID-19. Conversely, a number of patients also show non-respiratory symptoms, such as renal failure and other organs failure. The data about scRNA-seq of human heart demonstrated that > 7.5 percent myocardial cells encompass positive ACE2 expression, in that way entail that heart possibly will be in elevated possibility of involvement in COVID-19 infection [6]. This study has been designed to assess the severity and outcome in COVID19 patients having co-morbidities.

2. METHODS

This cross sectional research study was conceded on patients with definite COVID-19 infection and hospitalized at ICUs, wards of Jinnah Postgraduate Medical Center Karachi from March to June 2021. The enrolled patients diagnosed with COVID-19 according to the provisional directions given by WHO and the clinical outcomes measured. Comorbidities were determined based on patients self-report on admission. Data analyzed on SPSS version 22.0.

3. RESULTS

Total 200 COVID patients enrolled in the study, out of them 179 were with comorbidities like type 2 Diabetes mellitus, hypertension, cardiac disorder and asthma while 21 COVID patients were with no known co morbidity.

In present study (n=200), 55.5% were belonging to the age group more than fifty five years old, 50.5% were male , and 29.5% patients came in the month of June 2021. (As shown in Table No.1) There were 84% hypertensive, 54% were diabetic, 10% were IHD and 5% were Asthmatic patients (As shown in table no. 2).

Clinical outcomes, i.e., pneumothorax, pulmonary embolism, MI, septic shock, heart failure, DIC were associated with co-morbidities at the time of admission, p-value was <0.01 and $\chi^2=20.15$ (Table 3).
Table 1. Baseline Characteristics of studied population (n=200)

| Characteristics           | n   | %     |
|---------------------------|-----|-------|
| Age Group (Years)         |     |       |
| 17 - 35                   | 18  | 9.0   |
| 36 - 55                   | 71  | 35.5  |
| >55                       | 111 | 55.5  |
| Gender                    |     |       |
| Female                    | 99  | 49.5  |
| Male                      | 101 | 50.5  |
| Month                     |     |       |
| March                     | 50  | 25.0  |
| April                     | 43  | 21.5  |
| May                       | 48  | 24.0  |
| June                      | 59  | 29.5  |

Table 2. Co-morbidities in participants (n=200)

| Co morbidities            | n   | %     |
|---------------------------|-----|-------|
| Hypertension              |     |       |
| Yes                       | 168 | 84.0  |
| No                        | 32  | 16.0  |
| Diabetes Mellitus         |     |       |
| Yes                       | 108 | 54.0  |
| No                        | 92  | 46.0  |
| Ischemic Heart Disease    |     |       |
| Yes                       | 20  | 10.0  |
| No                        | 180 | 90.0  |
| Asthma                    |     |       |
| Yes                       | 10  | 5.0   |
| No                        | 190 | 95.0  |

Table 3. Clinical outcome in COVID patients with presence of co-morbidities (n=200)

| Clinical outcome                  | Yes n (%) | Co-morbidities | Total n (%) |
|-----------------------------------|-----------|----------------|-------------|
| Pneumothorax                      | 39 (19.5) | 0 (0)          | 39 (19.5)   |
| Pulmonary embolism                | 28 (14.0) | 4 (2.0)        | 32 (16.0)   |
| Myocardial infarction             | 25 (12.5) | 2 (1.0)        | 27 (13.5)   |
| Stroke                            | 10 (5.0)  | 0 (0)          | 10 (5.0)    |
| Septic shock                      | 10 (5.0)  | 0 (0)          | 10 (5.0)    |
| Heart failure                     | 10 (5.0)  | 0 (0)          | 10 (5.0)    |
| Disseminated intravascular        | 13 (6.5)  | 1 (5.0)        | 14 (7.0)    |
| coagulation                       | 44 (22.0) | 14 (7.0)       | 58 (29.0)   |
| Discharged within 2 days          |          |                |             |
| Total                             | 179 (89.5)| 21 (10.5)      | 200 (100)   |

*p-value =0.005 and \( \chi^2 =20.15 \) n = Number, % = Percentage

4. DISCUSSION

In present study, total 200 COVID patients enrolled in the study, out of them 179 were with comorbidities, i.e., 84% hypertensive, 54% were diabetic, 10% were IHD and 5% were asthmatic patients. Frequently observed clinical outcomes in COVID patients with comorbidities were pneumothorax, pulmonary embolism, MI, septic shock, heart failure, DIC. Similar to this study, Bajgain KT, et al. [4] also revealed hypertension, diabetes and cardiovascular diseases as commonly occurring co-morbidities in the COVID-19 patients world-wide. Huang C et al [7].

278
revealed about occurrence of pneumonia in such patients and the frequent complications of acute respiratory distress syndrome, acute cardiac injury and also the secondary infection. Invasive mechanical ventilation be required in 10 percent of these patients, with 5 percent suffering from refractory hypoxemia and conventional extracorporeal membrane oxygenation as salvage therapy. Guan WJ, et al., [8] revealed that 20–51% of patients on admission, reported as having at least one comorbidity, i.e., 10 to 20 percent diabetic, 10–15 percent hypertensive and also cardiovascular and cerebrovascular co-morbidities. They concluded that confirmed cases of COVID-19 infection presenting with any co morbidity yield poor clinical outcomes as compared to those having no co-morbid condition. M Madjid et al. [9] observed that COVID-19 infection may lead to the viral pneumonia with further extra pulmonary involvement signs and might culminate in fatal complications. Most of the patients found with underlying co-morbid condition involving cardiovascular system. Feature linked with death in such patients encompass male gender, old age, and presence of co-morbid conditions i.e., hypertension or diabetes mellitus or cardiovascular diseases or cerebrovascular accidents. In severe cases, troponin levels found elevated i.e., indicating cardiac involvement and this might lead to death. COVID-19 cases with acute respiratory distress syndrome also found associated with mortality.

The average observed case-fatality ratio is around 4% but this vary widely. Previous reports suggested that old age patients with diabetes and hypertension, go through more complications as compared to younger patients. However, younger patients with no obvious disease also emerge prone to rapid progression to critical disease and finally to death [10, 11].

A multi-center study, [12] found the independent risk factors associated with mortality in COVID-19 patients were hypercholesterolemia, type 2 diabetes mellitus, chronic obstructive pulmonary disease, old age, male gender, high positive end-expiratory pressure or low Pao2:Fio2 ratio on ICU admission and high fraction of inspired oxygen. Jain V et al. [13] revealed that dyspnea was the only warning sign predictive of fatal COVID-19 condition and ICU admission. COVID-19 has a varied clinical presentation. Elderly patients with other co-morbid conditions have been found more susceptible to fatal clinical outcomes.

5. CONCLUSION

COVID-19 patients with co-morbidities are more at risk of developing worst clinical outcomes.

CONSENT AND ETHICAL APPROVAL

This study was approved by the Ethical review committee of institute. Written informed consent was putted aside due to the infection related trouble and stress.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Galbraith MD, Kinning KT, Sullivan KD, Baxter R, Araya P, Jordan KR, Russell S, Smith KP, Granrath RE, Shaw JR, Dzieciatkowska M. Seroconversion stages COVID19 into distinct pathophysiological states. Elife. 2021;10:e65508.
2. Ammar A, Trabelsi K, Brach M, Chtourou H, Boukhris O, Masmoudi L, Bouaziz B, Bentlage E, How D, Ahmed M, Mueller P. Effects of home confinement on mental health and lifestyle behaviours during the COVID-19 outbreak: Insights from the ECLB-COVID19 multicentre study. Biology of Sport. 2021;38(1):9.
3. Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, Xiao W, Wang YN, Zhong MH, Li CH, Li GC. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chinese Medical Journal. 2020 May 5;133(9):1025.
4. Bajgain KT, Badal S, Bajgain BB, Santana MJ. Prevalence of comorbidities among individuals with COVID-19: A rapid review of current literature. American Journal of Infection Control. 2021;49(2):238-46.
5. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Yu T. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. The Lancet. 2020;395(10223):507-13.
6. Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the
potential risk of different human organs vulnerable to 2019-nCoV infection. Frontiers of Medicine. 2020 Mar 12;1-8.

7. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223): 497-506.

8. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, Liu XQ, Chen RC, Tang CL, Wang T, Ou CQ. Comorbidity and its impact on 1590 patients with COVID-19 in China: A nationwide analysis. European Respiratory Journal. 2020 May 1;55(5).

9. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential effects of coronaviruses on the cardiovascular system: A review. JAMA Cardiology. 2020;5(7):831-40.

10. Pathangey G, Fadadu PP, Hospodar AR, Abbas AE. Angiotensin-converting enzyme 2 and COVID-19: Patients, comorbidities, and therapies. American Journal of Physiology-Lung Cellular and Molecular Physiology. 2021;320(3):L301-30.

11. Lin Q, Zhao S, Gao D, Lou Y, Yang S, Musa SS, Wang MH, Cai Y, Wang W, Yang L, He D. A conceptual model for the coronavirus disease 2019 (COVID-19) outbreak in Wuhan, China with individual reaction and governmental action. International Journal of Infectious Diseases. 2020 Apr 1;93:211-6.

12. Grasselli G, Greco M, Zanella A, Albano G, et al. COVID-19 Lombardy ICU Network. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. JAMA Intern Med. 2020 Oct 1;180(10):1345-1355. DOI: 10.1001/jamainternmed.2020.3539 Erratum in: JAMA Intern Med. 2021 Jul 1;181(7):1021. PMID: 32667669; PMCID: PMC7364371.

13. Jain V, Yuan JM. Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: A systematic review and meta-analysis. International Journal of Public Health. 2020 Jun;65:533-46.

© 2021 Ghafar et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
https://www.sdiarticle5.com/review-history/78997